New drug trial aims to slow scarring in fatal lung disease
NCT ID NCT07464912
Summary
This large, late-stage trial is testing whether a new medicine called TDI01 can help people with Idiopathic Pulmonary Fibrosis (IPF), a serious disease that scars the lungs. Over 500 participants in China will receive either TDI01 or a placebo for a year to see if it can slow the decline in lung function. The study will also measure how well patients can walk and their quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China-Japan Friendship Hospital
RECRUITINGBeijing, Beijing Municipality, 100023, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.